Calibrating spectrometers for measurements of the spectral irradiance caused by solar radiation

Measuring the spectral irradiance of solar radiation is required in many fields of science and technology. In this work, we present an in-depth discussion of the measuring procedure and required corrections for such measurements. We also describe our measurement uncertainty analysis, which is based on a Monte-Carlo procedure in accordance with the Guide to the expression of uncertainty in measurement (JCGM, Paris, 2008). For this purpose, fifteen uncertainty sources are identified, analyzed and described analytically. As a specific application example, we describe the instrumentation and procedure for determining the spectral irradiance of a solar simulator at the ISO/IEC 17 025 accredited solar cell calibration laboratory ISFH CalTeC and the corresponding measurement uncertainty analysis. Moreover, we provide a Python implementation for this calculation along with the paper. We show that for state-of-the-art instrumentation, significant uncertainty contributions arise from the reference lamp (primary calibration standard), stray light and signal-to-noise ratio. If sharp spectral features are present (which is common, e.g. for Xenon lamps), spectral bandwidth and wavelength uncertainty also contribute significantly to the overall uncertainty. © 2020 BIPM & IOP Publishing Lt

Corrigendum: Calibrating spectrometers for measurements of the spectral irradiance caused by solar radiation (2020 Metrologia 57 065027)

We correct an error in equation (60) of the original publication

Expression of ABC Efflux Transporters in Placenta from Women with Insulin-Managed Diabetes

Drug efflux transporters in the placenta can significantly influence the materno-fetal transfer of a diverse array of drugs and other xenobiotics. To determine if clinically important drug efflux transporter expression is altered in pregnancies complicated by gestational diabetes mellitus (GDM-I) or type 1 diabetes mellitus (T1DM-I), we compared the expression of multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2) and the breast cancer resistance protein (BCRP) via western blotting and quantitative real-time polymerase chain reaction in samples obtained from insulin-managed diabetic pregnancies to healthy term-matched controls. At the level of mRNA, we found significantly increased expression of MDR1 in the GDM-I group compared to both the T1DM-I (p<0.01) and control groups (p<0.05). Significant changes in the placental protein expression of MDR1, MRP2, and BCRP were not detected (p>0.05). Interestingly, there was a significant, positive correlation observed between plasma hemoglobin A1c levels (a retrospective marker of glycemic control) and both BCRP protein expression (r = 0.45, p<0.05) and BCRP mRNA expression (r = 0.58, p<0.01) in the insulin-managed DM groups. Collectively, the data suggest that the expression of placental efflux transporters is not altered in pregnancies complicated by diabetes when hyperglycemia is managed; however, given the relationship between BCRP expression and plasma hemoglobin A1c levels it is plausible that their expression could change in poorly managed diabetes